Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$254.45 - $351.06 $2.6 Million - $3.58 Million
-10,200 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$272.01 - $353.03 $1.39 Million - $1.8 Million
5,100 Added 100.0%
10,200 $3.57 Million
Q3 2021

Nov 15, 2021

BUY
$295.0 - $350.58 $1.5 Million - $1.79 Million
5,100 New
5,100 $1.54 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $24.1B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Point State Capital LP Portfolio

Follow Point State Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Point State Capital LP with notifications on news.